Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant in Preoperative Early Breast Cancer
NCT04797728Phase 1Completed
- Sponsor
- SOLTI
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elacestrant in breast cancer, sponsored by SOLTI. Primary endpoint: Complete Cell Cycle Arrest (Ki67 <= 2.7%) at 4 weeks. Started Feb 2021; status: completed.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04797728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797728.